文献速递甲状腺疾病

美国癌症联合委员会/国际抗癌联盟分化型甲状腺癌第七版与第八版肿瘤-淋巴结-转移分期系统的比较

Comparison of the Seventh and Eighth Editions of the American Joint Committee on Cancer/Union for International Cancer Control Tumor-Node-Metastasis Staging System for Differentiated Thyroid Cancer.
PubMed 文献 · Thyroid · 2017-07-24

该研究对1996至2003年间接受甲状腺手术的1613例分化型甲状腺癌患者应用第七版与第八版TNM分期,比较两版对疾病特异性生存的预测能力。结果显示第八版使约38%患者降期,第八版预测疾病特异性生存的准确度有所提高。

要点

  • 第八版TNM分期使约38%的分化型甲状腺癌患者降期。
  • 第八版TNM-8的Harrell c-index为0.88,高于第七版的0.86。
  • 第八版对疾病特异性生存的预测准确度有所提高。

核心结论

  • 应用第八版TNM分期后,相当数量的分化型甲状腺癌患者被重新分类至较低分期。
  • 应用第八版可能提高分期系统对分化型甲状腺癌患者疾病特异性生存的预测准确度。

研究设计与样本

  • 对1996至2003年间接受甲状腺手术的1613例分化型甲状腺癌患者应用第七版与第八版TNM分期。
  • 评估比例变异解释度与Harrell c-index以比较两版对疾病特异性生存的预测能力。

主要发现

  • 患者平均年龄44.7岁,中位随访期11.2年。
  • 应用第八版时,63%的T3期和3%的N1b期分化型甲状腺癌分别降期为T1/T2期和N1a期。
  • 约38%的患者按第八版降期。
  • 第七版I、II、III、IV期的10年疾病特异性生存率分别为99.7%、98.2%、98.8%和83.2%,第八版I、II、III、IV期分别为99.6%、95.4%、72.3%和48.6%。
  • 第七版与第八版的比例变异解释度分别为6.0%和7.0%,Harrell c-index分别为0.86和0.88。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and prognostic validity for disease-specific survival (DSS) of the eighth edition American Joint Committee on Cancer/Union for International Cancer Control tumor-node-metastasis (TNM) staging system (TNM-8) compared to the seventh edition (TNM-7) in patients with differentiated thyroid carcinoma (DTC). METHODS: The seventh and eighth editions of the TNM staging system were applied to 1613 DTC patients who underwent thyroid surgery between 1996 and 2003. The proportion of variation explained and Harrell's c-index were evaluated to compare the predictive capability of DSS. RESULTS: The mean age of the patients was 44.7 years, and the median follow-up period was 11.2 years. When TNM-8 was applied, 63% of T3 and 3% of N1b DTCs were downgraded to T1/T2 and N1a, respectively. About 38% of patients were downstaged according to TNM-8. The 10-year DSS rates in TNM-7 stages I, II, III, and IV were 99.7%, 98.2%, 98.8%, and 83.2%, respectively. Those in TNM-8 stages I, II, III, and IV were 99.6%, 95.4%, 72.3%, and 48.6%, respectively. The proportion of variation explained values of TNM-7 and TNM-8 were 6.0% and 7.0%, respectively. The Harrell's c-index of TNM-7 was 0.86 and that of TNM-8 was 0.88. CONCLUSIONS: A significant number of patients were reclassified to lower stages with the application of TNM-8 compared to TNM-7. Applying TNM-8 could improve the accuracy of the staging system for predicting DSS in patients with DTC.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Kim M, Kim WG, Oh HS, et al. Comparison of the Seventh and Eighth Editions of the American Joint Committee on Cancer/Union for International Cancer Control Tumor-Node-Metastasis Staging System for Differentiated Thyroid Cancer. Thyroid. 2017. PMID: 28635571. doi:10.1089/thy.2017.0050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。